- Kaynes Convention Centre
- July 25, 2026
- 09:00 - 12:10
Breast Cancer
Chairperson
Chairperson
Dr Poonam Patil
Manipal Hospitals
09:00
From Biomarkers to Targeted Therapy: Recent Molecular Advances in Breast Cancer
Speaker
Dr Aruna Korlimarla
Sri Shankara Cancer Foundation
09:15
LBA503 - Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial.
Speaker
Dr Vijaykumar M
BHIO
LBA515 - Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.
Speaker
Dr Anup R Hegde
KIMS
500 - First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
Speaker
Dr S Vishnu Vardhan Yedla
Vydehi Inst. Med. Sci.
502 - Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
Speaker
Dr Sneha Kommineni
Aster
507 - Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.
Speaker
Dr Vivek B Maleyur
Kidwai Mem. Inst. Onc.
09:45
Panel Discussion: Molecular MDT: Achieving favourable responses each time
Moderator
Dr Nishita Shetty
Father Muller Med. Coll. Hosp.
Panelists
Dr Anup R Hegde
KIMS
Panelists
Dr Sneha Kommineni
Aster
Panelists
Dr Vijaykumar M
BHIO
Panelists
Dr S Vishnu Vardhan Yedla
Vydehi Inst. Med. Sci.
Panelists
Dr Vivek B Maleyur
Kidwai Mem. Inst. Onc.
10:05
Industry Session : Eli Lilly
Topic: Identifying & Managing the High Risk HR+ HER2-Ve Node positive Early & Metastatic Breast Cancer Patients.
Speaker
Dr Vaishnavi Joshi
10:35
Industry Session : MSD
Topic: Redefining Treatment Outcomes With Immunotherapy: Early Triple Negative Breast Cancer (TNBC)
Speaker
Dr Pragnya Coca
Chairperson
Chairperson
Dr Govind Babu
HCG Hospitals
10:55
LBA1000 - Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.
Speaker
Dr Prakash Mishra
Vydehi Hospital
LBA1007 - First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.
Speaker
Dr Santosh K N
BHIO
LBA1018 - Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.
Speaker
Dr Kiran P K
JSS Medical College
1002 - First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
Speaker
Dr Naveen Jayaram Anvekar
Apollo Hospitals
1005 - Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
Speaker
Dr Kiranmala Keithellakpam
Bangalore Baptist Hospital
11:25
Industry Session : AstraZeneca
Topic: Redefining Outcomes in 1L HER2+ mBC with ENHERTU® + Pertuzumab
Speaker
Dr CN Patil
11:45
Industry Session: Novartis
Panel Discussion Topic: Reduce the risk of recurrence in HR+/HER2 - EBC
Moderator
Dr Satheesh CT
Panelists
Dr Abhilash GH
Panelists
Dr Rajeev Vijaykumar
12:15
Panel Discussion: The Future of Immunotherapy for Breast Cancer
Moderator
Dr Prajwal K P
Fortis Hospital
Panelists
Dr Kiran P K
JSS Medical College
Panelists
Dr Kiranmala Keithellakpam
Bangalore Baptist Hospital
Panelists
Dr Naveen Jayaram Anvekar
Apollo Hospitals
Panelists
Dr Prakash Mishra
Vydehi Hospital
Panelists
Dr Santosh K N
BHIO
12:35
Expert Comments
Speaker
Dr Aditya Murali
HCG Hospitals
- Kaynes Convention Centre
- July 25, 2026
- 12:40 - 13:00
Inauguration
Lighting of the Lamp & Welcome Address
- Kaynes Convention Centre
- July 25, 2026
- 13:00 - 13:30
Keynote
13:00
Keynote Talk: The Exposome, Cancer Risk, and Cancer Care: Understanding the Environmental Impact on Malignancy
Chairperson
Dr Kumara Swamy
HCG Hospitals
Speaker
Dr Prashanth Mathur
ICMR-NINE
- Kaynes Convention Centre
- July 25, 2026
- 13:30 - 14:00
Lunch
- Kaynes Convention Centre
- July 25, 2026
- 14:00 - 16:05
Lung Cancer
14:00
Industry Panel Discussion: J & J
Topic: A Tale of Two Stories- Redefining Treatment Outcomes With Mariposa 2 And Papillon
Chairperson
Dr Suresh Babu
KIMS Hospitals
Moderator
Dr Ravi Tippeswamy
Panelists
Dr Annie K
Panelists
Dr Avinash CB
Panelists
Dr Kaushik M R
Panelists
Dr Sateesh CT
14:20
Invited Talk: Evolution of Immunotherapy in NSCLC
Speaker
Dr Govind Babu
HCG Hospitals
14:35
8001 - Adjuvant erlotinib versus observation after complete resection of EGFR-mutant NSCLC: Final overall survival results of Alliance A081105.
Speaker
Dr Deepa Aggarwal
KIMS
8015 - Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
Speaker
Dr. Sreevalli Anantharamu
Manipal Hospitals
8016 - Tumor-naïve multimodal cfDNA MRD assay to predict recurrence in a prospective cohort of patients undergoing curative-intent lung cancer resection.
Speaker
Dr Kaushik M R
Command Hospital Air Force
8501 - Overall survival of first-lineivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.
Speaker
Dr Naveen Jayaram Anvekar
Apollo Hospitals
8502 - Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Speaker
Dr Prathyusha Eaga
KIMS Hospital
8504 - Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
Speaker
Dr Abhilash G H
BHIO
8624 - Wait or treat? managing asymptomatic brain metastases in oncogene-mutated NSCLC: Results of a phase-III randomized controlled trial.
Speaker
Dr Rejil Rajan
Clearmedi
15:20
Industry Session : BMS
TOPIC: 1L NSCLC (5 year update)
Speaker
Dr Rajeev Vijaykumar
15:40
Panel Discussion: How does latest Evidence impact India Practice
Moderator
Dr Ganesha Dev Vashishta
St Johns Hospital
Panelists
Dr Abhilash G H
BHIO
Panelists
Dr Deepa Aggarwal
KIMS
Panelists
Dr Koushik M R
Command Hospital Air Force
Panelists
Dr Prathyusha Eaga
KIMS Hospital
Panelists
Rejil Rajan
Clearmedi
Panelists
Dr Srivalli Anantharamu
Manipal Hospitals
16:00
Expert Comments
Speaker
Dr Suresh Babu
KIMS Hospital
16:05
Industry Session : MSD
TOPIC: Treatment Evolution of Nonsquamous Non-small Cell Lung Cancer
Speaker
Dr CN Patil
- Kaynes Convention Centre
- July 25, 2026
- 16:25
Tea Break
- Kaynes Convention Centre
- July 25, 2026
- 16:00 - 16:50
Head and Neck Cancer
16:00
6013 - Induction chemotherapy with nab-paclitaxel and cisplatin versus docetaxel, cisplatin, and fluorouracil followed by chemoradiotherapy in patients with stage III-IVA nasopharyngeal carcinoma: An open-label, noninferiority, randomized, controlled, phase 3 trial.
Speaker
Dr Lepakshi Kuruba
Narayan Health
6057 - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Efficacy by surgical outcomes in the phase 3 KEYNOTE-689 trial.
Speaker
Dr Adithya Krishna
HCG Hospital
6086 - Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer: 3-year follow-up of the INSIGHT study.
Speaker
Dr Annie Kanchan Baa
St Johns Medical College Hospital
6101 - Comparison of efficacy between 2 and 3 cycles of neoadjuvant immunotherapy combined with chemotherapy for LA HNSCC.
Speaker
Dr Spoorthi Reddy
Apollo Hospital
LBA6007 - Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
Speaker
Dr Sanal Fernandes
St Johns Med. Coll. Hospital
16:30
Panel Discussion: How does latest Evidence impact India Practice
Moderator
Dr Satheesh CT
HCG Hospitals
Panelist
Dr Adithya Krishna
HCG Hospitals
Panelist
Dr Annie K
St Johns Medical College Hospital
Panelist
Dr Lepakshi Kuruba
Narayan Health
Panelist
Dr Sanal Fernandes
St Johns Medical College Hospital
Panelist
Dr Spoorthi
Apollo Hospital
4:50
Industry Session : MSD
Topic: Role of Immunotherapy in 1st Line R/M HNSCC
Speaker
Dr Anup R Hegde
- Kaynes Convention Centre
- July 25, 2026
- 17:10 - 18:20
India @ ASCO
17:10
Panel Discussion: India @ ASCO
Chairperson
Dr Ramesh Bilimagga
HCG Hospitals
Moderator
Dr Shobha Vijayaraghavan
Accenture
Panelist
Dr Anbarasan Shekhar
TMH
Panelist
Dr Aruna Korlimarla
Shri Shankara
Panelist
Dr Krithika Sekhar
HCG
Panelist
Dr Lohit Reddy
HCG
Panelist
Dr Prashanth Mathur
ICMR, NINE
17:50
Plenary Presentation
Chairperson
Dr Ramesh Bilimagga
HCG Hospitals
Dr B S Ajaikumar
Founder & Chairman - HCG
